Skip to main content
Premium Trial:

Request an Annual Quote

Envoy to Screen Targets for Takeda Pharmaceutical

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Envoy Therapeutics and Takeda Pharmaceutical have formed a three-year alliance to discover drug candidates for treating schizophrenia, the firms announced today.

Jupiter, Fla.-based Envoy will use its bacTrap technology, which combines genetic engineering with new molecular biology techniques for labeling and extracting the protein-making components of specific types of cells. The technology, which was developed at Rockefeller University, enables identification of new drug targets by measuring the in vivo expression of translated genes in specific, medically relevant cell types among the intermingled cell types present in the central nervous system without requiring the isolation of cells, said Envoy.

Envoy researchers aim to identify proteins that are selectively expressed in specific cell types within the brain that are known to be affected in patients with schizophrenia. The firms will then collaborate on evaluating and selecting proteins that hold the greatest potential for therapeutic modulation.

Under terms of the pact, Osaka, Japan-based Takeda will make a $3 million upfront payment to Envoy and provide $2.25 million per year in research funding and fees. In addition, Envoy will receive potential milestone payments and royalties should one or more compounds advance to clinical development and commercialization.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.